ARCT News and Press, Arcturus Therapeutics Ltd. From 12/07/20

Gainers: [[SFIX]] +33.8%. [[PLG]] +16.9%. [[SMAR]] +14.6%. [[HOLI]] +12.7%. [[KODK]] +8.6%.Losers: [[FRAN]] -19%. [[OBLN]] -11.3%. [[ARCT]] -6%. [[STRO]] -4%. [[EVK]] -3%. For further details see: SFIX, KODK, ARCT and FRAN among after-hours movers

Arcturus Therapeutics (ARCT) intends to offer and sell shares of its common stock in an underwritten public offering.Underwriter's option to purchase additional 15% of the offering.Size and terms yet to be finalised.Press Release For further details see: Arcturus Therapeutics propo...

Arcturus Therapeutics (NASDAQ:ARCT) has initiated the dosing in its Phase 1b study of ARCT-810, its leading rare disease asset targeting Ornithine Transcarbamylase deficiency, a urea cycle disorder with no FDA-approved therapy.OTC deficiency affects approximately 10,000 people world...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...

You'd nearly have to live in a cave to not hear about the major advances for the leading coronavirus vaccines. Pfizer and BioNTech have already won authorization in the U.K. for their vaccine, BNT162b2, which could receive U.S. emergency use authorization within weeks. So could ...

ARKG aims to capitalize on a $9Tn TAM with the convergence of AI, DNA Sequencing and Gene-Editing. ARKG is up 149% YTD vs. the SPX return of 13%. Led by Cathie Wood, I think ARKG will be the best performing ARK Fund over the next 10 years. For further details see: ARKG: ...

Healthcare experienced a significant risk-diminishing event as the Affordable Care Act appears more secure. Biotechs continue to lead healthcare as vaccine progress and key approvals draw significant attention. Drug pricing remains a dormant issue for now although key moves last w...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...

Gainers: SCWorx (WORX) +80%.FreightCar America (RAIL) +48%.ReneSola (SOL) +44%.Oramed Pharmaceuticals (ORMP) +40%.Apex Technology Acquisition (APXT) +30%.Kaleyra (KLR) +29%.Rhythm Pharmaceuticals (RYTM) +27%.Aurora Mobile (JG) +27%.Novavax (NVAX) +20%.Arcturus Therapeutics (ARC...

Shares of Arcturus Therapeutics Holdings (NASDAQ: ARCT) were soaring 12.7% higher as of 3:28 p.m. EST on Tuesday. The big jump came after the clinical-stage biotech provided its third-quarter update following the market close on Monday. Investors were less interested in Arcturus' fi...